AU2006312119B2 - Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same - Google Patents

Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same Download PDF

Info

Publication number
AU2006312119B2
AU2006312119B2 AU2006312119A AU2006312119A AU2006312119B2 AU 2006312119 B2 AU2006312119 B2 AU 2006312119B2 AU 2006312119 A AU2006312119 A AU 2006312119A AU 2006312119 A AU2006312119 A AU 2006312119A AU 2006312119 B2 AU2006312119 B2 AU 2006312119B2
Authority
AU
Australia
Prior art keywords
formulation
ibuprofen
subject
cyclodextrin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006312119A
Other languages
English (en)
Other versions
AU2006312119A1 (en
Inventor
Toru Hibi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teikoku Pharma USA Inc
Original Assignee
Teikoku Pharma USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma USA Inc filed Critical Teikoku Pharma USA Inc
Publication of AU2006312119A1 publication Critical patent/AU2006312119A1/en
Application granted granted Critical
Publication of AU2006312119B2 publication Critical patent/AU2006312119B2/en
Priority to AU2010202050A priority Critical patent/AU2010202050A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2006312119A 2005-11-02 2006-10-17 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same Ceased AU2006312119B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010202050A AU2010202050A1 (en) 2005-11-02 2010-05-20 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73312705P 2005-11-02 2005-11-02
US60/733,127 2005-11-02
US81041706P 2006-06-01 2006-06-01
US60/810,417 2006-06-01
PCT/US2006/041024 WO2007055887A1 (en) 2005-11-02 2006-10-17 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010202050A Division AU2010202050A1 (en) 2005-11-02 2010-05-20 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Publications (2)

Publication Number Publication Date
AU2006312119A1 AU2006312119A1 (en) 2007-05-18
AU2006312119B2 true AU2006312119B2 (en) 2010-04-29

Family

ID=38023574

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006312119A Ceased AU2006312119B2 (en) 2005-11-02 2006-10-17 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
AU2010202050A Abandoned AU2010202050A1 (en) 2005-11-02 2010-05-20 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010202050A Abandoned AU2010202050A1 (en) 2005-11-02 2010-05-20 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Country Status (12)

Country Link
US (1) US20070098789A1 (enExample)
EP (1) EP1942877A4 (enExample)
JP (2) JP2009514857A (enExample)
KR (1) KR20080034166A (enExample)
CN (1) CN103622926A (enExample)
AR (1) AR056749A1 (enExample)
AU (2) AU2006312119B2 (enExample)
BR (1) BRPI0618273A2 (enExample)
CA (1) CA2620219A1 (enExample)
RU (2) RU2008116871A (enExample)
TW (1) TW200733954A (enExample)
WO (1) WO2007055887A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618273A2 (pt) * 2005-11-02 2011-08-23 Teikoku Pharma Usa Inc formulações de dosagem oral de ibuprofeno organolepticamente aceitáveis, métodos de produção e uso das mesmas
WO2008052033A2 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
JP5821247B2 (ja) * 2010-04-07 2015-11-24 大正製薬株式会社 イブプロフェンの昇華抑制方法
EP3178470A1 (en) * 2011-04-11 2017-06-14 Vitux Group AS Oral pharmaceutical dispersion compositions
CN102258490B (zh) * 2011-07-01 2012-10-03 中美天津史克制药有限公司 布洛芬咀嚼片
US9914968B2 (en) 2012-09-26 2018-03-13 Cepheid Honeycomb tube
FR2997856B1 (fr) * 2012-11-14 2015-04-24 Pf Medicament Pastille medicamenteuse a base d'ibuprofene sodique dihydrate
CN103690474B (zh) * 2013-12-04 2015-09-30 郑州大明药物科技有限公司 布洛芬乳膏的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2219585A (en) * 1988-06-09 1989-12-13 Reckitt & Colmann Prod Ltd Cyclodextrin/ibuprofen complexes
JPH0426618A (ja) * 1990-05-21 1992-01-29 Japan Tobacco Inc トローチ剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
CH677606A5 (enExample) * 1988-07-12 1991-06-14 Aesculapius Pharma Sa
US4916161A (en) * 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
US5055461A (en) * 1989-02-15 1991-10-08 Richardson-Vicks Inc. Anesthetic oral compositions and methods of use
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
GB9207990D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Pharmaceutical composition
JPH08509725A (ja) * 1993-04-30 1996-10-15 ザ、プロクター、エンド、ギャンブル、カンパニー コートされた医薬組成物
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5616344A (en) * 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5560913A (en) * 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
TW442287B (en) * 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
DE69617868T2 (de) * 1995-10-17 2002-06-20 Reckitt Benckiser Healthcare (Uk) Ltd., Slough Geschmacksmaskierte wässrige Lösungen enthaltend Ibuprofen und Menthol
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5912007A (en) * 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
AU3444297A (en) * 1996-07-12 1998-02-09 Novartis Consumer Health S.A. Oral pharmaceutical combinations of nsaids with terpenoids
GB9710521D0 (en) * 1997-05-22 1997-07-16 Boots Co Plc Process
WO1999055320A1 (en) * 1998-04-29 1999-11-04 Sumitomo Pharmaceuticals Co., Ltd. Oral formulation comprising biguanide and an organic acid
US20020110581A1 (en) * 1999-04-06 2002-08-15 Ream Ronald L. Over-coated product including consumable center and medicament
US20050042271A1 (en) * 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
ES2171110B1 (es) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
US20020022057A1 (en) * 2000-08-17 2002-02-21 Battey Alyce S. Oral delivery of pharmaceuticals via encapsulation
KR100762115B1 (ko) * 2000-08-25 2007-10-04 코와 가부시키가이샤 이부프로펜 캡슐 충전액 및 캡슐 제제
IT1319229B1 (it) * 2000-10-20 2003-09-26 Savio Macchine Tessili Spa Dispositivo portarocche perfezionato per avvolgimento di filato conpressione regolata, particolarmente per ritorcitoi a doppia torsione.
US20040147606A1 (en) * 2001-05-25 2004-07-29 Yoichi Onuki Medicinal compositions
US8859028B2 (en) * 2002-06-14 2014-10-14 Cereal Ingredients, Inc. Coated food particle and method for making a swirl
GB0217382D0 (en) * 2002-07-26 2002-09-04 Pfizer Ltd Process for making orally consumable dosage forms
US20040071852A1 (en) * 2002-10-09 2004-04-15 Yael Vodovotz Compositions and processes for making high soy protein-containing bakery products
EP1886582B1 (en) * 2002-10-11 2015-01-14 Novozymes A/S Method of preparing a heat-treated product
JP4815867B2 (ja) * 2004-05-11 2011-11-16 大正製薬株式会社 安定化された固形製剤
US20060263475A1 (en) * 2004-08-25 2006-11-23 Cadbury Adams Usa, Llc. Center-filled chewing gum composition
WO2006067593A1 (en) * 2004-12-23 2006-06-29 Mcneil-Ppc, Inc. Orally disintegrating pharmaceutical compositions with sensory cue agents
BRPI0618273A2 (pt) * 2005-11-02 2011-08-23 Teikoku Pharma Usa Inc formulações de dosagem oral de ibuprofeno organolepticamente aceitáveis, métodos de produção e uso das mesmas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2219585A (en) * 1988-06-09 1989-12-13 Reckitt & Colmann Prod Ltd Cyclodextrin/ibuprofen complexes
JPH0426618A (ja) * 1990-05-21 1992-01-29 Japan Tobacco Inc トローチ剤

Also Published As

Publication number Publication date
EP1942877A4 (en) 2011-09-14
US20070098789A1 (en) 2007-05-03
KR20080034166A (ko) 2008-04-18
CA2620219A1 (en) 2007-05-18
WO2007055887A1 (en) 2007-05-18
JP2012255018A (ja) 2012-12-27
CN103622926A (zh) 2014-03-12
JP2009514857A (ja) 2009-04-09
BRPI0618273A2 (pt) 2011-08-23
AU2006312119A1 (en) 2007-05-18
AU2010202050A1 (en) 2010-06-10
RU2012138581A (ru) 2014-03-20
EP1942877A1 (en) 2008-07-16
RU2008116871A (ru) 2009-12-10
AR056749A1 (es) 2007-10-24
TW200733954A (en) 2007-09-16

Similar Documents

Publication Publication Date Title
AU2010202050A1 (en) Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
US20090238905A1 (en) Inflammation reducing action of synergistic mixtures of bisabolol and ginger extracts
RU2218180C2 (ru) Комбинация анальгетиков
US10028967B2 (en) Medicament
JP5360368B2 (ja) 服用感が改善された経口用アミノ酸製剤
JP2001010977A (ja) 経口用組成物
DK2833880T3 (en) Oral solid dosage composition with ibuprofen comprising a methacrylic acid copolymer
JP5577168B2 (ja) 経口用医薬組成物
JP2007530688A (ja) 肝毒性が減少した組成物
HK1191560A (en) Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
CN101262854A (zh) 感官上可接受的布洛芬口服给药制剂、制备和使用它的方法
AU2004298763A1 (en) Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatability
EP3716944A1 (en) Stable liquid composition of ketoprofen, salts and enantiomers thereof
CN104640537A (zh) 用于口服剂型的低熔点丙酸衍生物粒子
FR2660195A1 (fr) Composition pharmaceutique a macher, antiinflammatoire et/ou analgesique.
ES2694710T3 (es) Comprimidos que comprenden un agente que enmascara el sabor
JPS62270523A (ja) 非刺激性のスプロフエン溶液
KR20190078455A (ko) 플루르비프로펜 함유 스프레이 조성물 및 그 제조방법
JP2004331660A5 (enExample)
CN104640570B (zh) 包含低熔点丙酸衍生物颗粒的混悬药物制剂
CN104640571A (zh) 包含低熔点丙酸衍生物颗粒的缓释口服剂型
AU2006252204B2 (en) Prevention of Flap Necrosis in Plastic Surgery
CN105168155A (zh) 可直接压制的丙酸衍生物颗粒
Shah Novel Pediatric Dosage Forms: Formulation Devlopment and Optimization
Gulagannavar Design and evaluation of orodispersible taste masked valdecoxib tablets

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired